19th Ave New York, NY 95822, USA
Join Now

Grup Melanoma i altres tumors cutanis

Portfolio Item Grup Melanoma i altres tumors cutanis
RECERCA CLÍNICA

El Grup de Recerca en Melanoma i Altres Tumors Cutanis del VHIO se centra principalment en la recerca clínica i translacional, amb una atenció especial al desenvolupament de noves teràpies dirigides, estratègies basades en immunoteràpia i a l’estudi dels mecanismes de resistència primària i adquirida als tractaments actuals.

La nostra activitat de recerca abasta tot l’espectre de subtipus de melanoma, inclosos el melanoma cutani, mucós, acral i uveal, així com altres tumors malignes de la pell, com el carcinoma cutani de cèl·lules escamoses i el carcinoma basocel·lular. Paral·lelament, liderem i participem en assaigs clínics de fases inicials i avançades en diferents estadis de la malaltia, inclosos els contextos metastàtic, neoadjuvant i adjuvant.

En els darrers anys, la nostra Unitat s’ha consolidat com a centre de referència nacional i internacional en el tractament i la recerca del càncer de pell. Aquest posicionament ha estat possible gràcies al desenvolupament d’un dels arsenals terapèutics més amplis en oncologia cutània, que permet als pacients accedir a fàrmacs innovadors i a assaigs clínics d’avantguarda.

El nostre model de recerca multidisciplinària i translacional constitueix una de les principals fortaleses del grup. L’equip integra oncòlegs mèdics, dermatòlegs, patòlegs, biòlegs moleculars, investigadors translacionals i altres especialistes mèdics, fet que afavoreix un flux bidireccional continu entre el laboratori i la pràctica clínica. Aquesta estructura ens ha permès coordinar i liderar una de les xarxes col·laboratives de melanoma més grans d’Espanya i Europa, impulsant iniciatives de recerca multicèntrica i col·laboracions internacionals.

Al llarg del 2025, hem continuat assolint avenços significatius mitjançant el lideratge, el colideratge i la participació en múltiples assaigs clínics de fases I a III que avaluen estratègies terapèutiques innovadores. Entre aquestes s’inclouen inhibidors de punts de control immunitari de nova generació, teràpies cel·lulars, combinacions de teràpies dirigides i nous enfocaments neoadjuvants i adjuvants. Paral·lelament, participem activament en projectes translacionals i guiats per biomarcadors, amb una atenció especial a comprendre i superar la resistència a les immunoteràpies estàndard i als tractaments dirigits.

Una de les nostres principals línies estratègiques de recerca és l’estudi dels esdeveniments adversos relacionats amb el sistema immunitari (irAE). En estreta col·laboració amb diferents serveis de l’Hospital Universitari Vall d’Hebron, entre els quals hi ha Medicina Interna, Cardiologia, Neurologia, Nefrologia, Hepatologia i Endocrinologia, hem consolidat un Grup de Treball sobre Toxicitat de la Immunoteràpia. Aquesta iniciativa multidisciplinària té com a objectius:

  • Millorar la identificació precoç i el maneig de les toxicitats relacionades amb el sistema immunitari.
  • Harmonitzar els circuits assistencials i avançar en la recerca clínica i translacional sobre els mecanismes biològics que subjauen als irAE.

Mitjançant aquest enfocament integrat, el Grup de Recerca en Melanoma i Altres Tumors Cutanis del VHIO continua reforçant el seu compromís amb l’oncologia de precisió, la innovació centrada en el pacient i la translació dels descobriments científics en beneficis clínics tangibles.

Eva Muñoz
Cap de grup
Biosketch

Línies de recerca

  • Consolidar la nostra Unitat de Tumors Cutanis com a centre de referència nacional i internacional en melanoma i altres càncers de pell, reforçant una xarxa de derivació ja consolidada i continuant amb el lideratge, el colideratge i la participació activa en assaigs clínics a gran escala des de les primeres etapes del seu disseny, planificació i implementació.
  • Millorar els resultats clínics dels pacients amb melanoma cutani i ocular, alhora que aprofundim en el coneixement dels mecanismes biològics que intervenen en l’inici i la progressió de la malaltia i en la resposta al tractament.
  • Impulsar el desenvolupament clínic inicial de fàrmacs, centrat en la identificació i validació de biomarcadors de progressió tumoral, resposta terapèutica i resistència, així com en el desenvolupament de noves dianes terapèutiques per al melanoma i altres tumors malignes cutanis.
  • Ampliar i reforçar les col·laboracions amb altres grups de recerca del VHIO i impulsar projectes translacionals integrats orientats a assolir una comprensió més completa de la immunologia tumoral i la biologia molecular dels càncers de pell.
  • Esclarir els mecanismes moleculars i cel·lulars que impulsen el desenvolupament i la progressió dels càncers de pell no melanoma, amb una atenció especial al carcinoma cutani de cèl·lules escamoses i al carcinoma basocel·lular.
  • Identificar i validar dianes moleculars susceptibles d’intervenció terapèutica, incloses les implicades en el metabolisme tumoral, per ampliar i diversificar l’arsenal terapèutic disponible per als pacients amb tumors cutanis.

Equip

Cap del grup
Eva Muñoz
Oncòlogues mèdiques i investigadores clíniques
Julia Lostes, Giulia Petrelli

Publicacions

Publicacions científiques més rellevants

  1. Robert C, Kicinski M, Dutriaux C, Routier É, Govaerts AS, Bührer E, Neidhardt EM, Durando X, Baroudjian B, Saiag P, Gaudy-Marqueste C, Ascierto PA, Arance A, Russillo M, Perrot JL, Mortier L, Aubin F, Dalle S, Grange F, Muñoz-Couselo E, Mary-Prey S, Amini-Adle M, Mansard S, Lebbe C, Funck-Brentano E, Monestier S, Eggermont AMM, Oppong F, Wijnen L, Schilling B, MandalÁ M, Lorigan P, van Akkooi ACJ. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2025 Jun;26(6):781-794.
  2. Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med. 2025 Dec;31(12):4301-4309.
  3. Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. Nat Med. 2025 Nov;31(11):3700-3712.
  4. Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Muñoz-Couselo E, Burris HA 3rd, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. Clin Cancer Res. 2025 Jun 3;31(11):2097-2107.
  5. Spreafico A, Couselo EM, Irmisch A, Bessa J, Au-Yeung G, Bechter O, Svane IM, Sanmamed MF, Gambardella V, McKean M, Callahan M, Dummer R, Klein C, Umaña P, Justies N, Heil F, Fahrni L, Opolka-Hoffmann E, Waldhauer I, Bleul C, Staack RF, Karanikas V, Fowler S. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. Front Oncol. 2024 Mar 21;14:1346502.
  6. McGrail K, González-Sánchez E, Granado-Martínez P, Orsenigo R, Ding Y, Ferrer B, Hernández-Losa J, Ortega I, Martín-Caballero J, Muñoz-Couselo E, García-Patos V, Recio JA. Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation. Mol Oncol. 2024. doi: 10.1002/1878-0261.13715.
  7. Gogas H, Ravimohan S, Datta A, Chhibber A, Couselo EM, Diab A, Pereira C, Quéreux G, Sandhu S, Curti B, Khushalani NI, Taylor MH, Daniels GA, Spreafico A, Meniawy T, Van Den Eertwegh AJM, Sun Y, Arriaga Y, Zhou M, Long GV, Lebbé C. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab. NPJ Precis Oncol. 2024 Jul 19;8(1):150.
  8. Usset J, Rosendahl Huber A, Andrianova MA, Batlle E, Carles J, Cuppen E, Elez E, Felip E, Gómez-Rey M, Lo Giacco D, Martinez-Jimenez F, Muñoz-Couselo E, Siu LL, Tabernero J, Vivancos A, Muiños F, Gonzalez-Perez A, Lopez-Bigas N. Five latent factors underlie response to immunotherapy. Nat Genet. 2024 Oct;56(10):2112-2120.
  9. Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265.
  10. de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. J Clin Oncol. 2023 May 10;41(14):2651-2660.
  11. Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Muñoz Couselo E, Bronzon Damian F, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. J Clin Oncol. 2023 Oct 20;41(30):4756-4767.
  12. Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, Arance AM, Grange F, Meyer N, Joshi AJ, Billan S, Hughes BGM, Grob JJ, Ramakrishnan K, Ge J, Gumuscu B, Swaby RF, Gutzmer R. Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. Dermatol Ther (Heidelb). 2023 Dec;13(12):3165-3180.
  13. Kimberley McGrail, Ms Sara García-Ortega, Paula Granado-Martinez, Dr Rosaura Estéve-Puig, Ms Sara Sanchez-Redondo, Dr Berta Ferrer, Dr Javier Hernandez-Losa, Dr Francesc Canals, Dr Anna Manzano, Aurea Navarro-Sabaté , Ramon Bartrons , Dr Mileidys Pérez-Alea , Eva Muñoz Couselo , Vicenç Garcia-Patos. BRAF activation by metabolic stress promotes glycolysis and survival, sensitizing NRASQ61 mutated melanomas to targeted therapy. Nature Communications | (2022) 13:7113; https://doi.org/10.1038/s41467-022-34907-0
  14. Ana Amor Lopez, Marina Mazariegos, Marta Hergueta-Redondo, Alessandra Capuano, Pilar Ximénez-Embún, Héctor Tejero, Javier Muñoz, Juan Recio, Eva Muñoz-Couselo, Roberto Doliana, Roberto Doliana, Paola Spessotto, and Hector Peinado. Inactivation of EMILIN-1 by proteolysis and secretion in extracellular vesicles favours melanoma progression and metástasis. Int. J. Mol. Sci. 2021, 22, 7406. https://doi.org/10.3390/ ijms22147406
  15. B. G. M. Hughes, E. Munoz-Couselo, L. Mortier, Å. Bratland4, R. Gutzmer, O. Roshdy, R. González Mendoza, J. Schachter, A. Arance, F. Grange N. Meyer, A. Joshi, S. Billan, P. Zhang, B. Gumuscu, R. F. Swaby, J-J Grob. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial. Ann Oncol. 2021 Jul 19: S0923-7534(21)02186-4. doi: 10.1016/j.annonc.2021.07.008. Online ahead of print. PMID: 34293460
  16. Maria Gonzalez-Cao1; Clara Mayo de las Casas1; Juana Oramas2; Miguel A Berciano3; Luis de la Cruz4; Pablo Cerezuela5; Ana Arance6; Eva Muñoz7; Enrique Espinosa8; Teresa Puertolas9; Roberto Diez10; Sebastian Ochendustko11; Maria Jose Villanueva12; Laura Basterretxea13; Lorena Bellido14; Delvys Rodriguez15; Begoña Campos16; Clara Montagut17; Ana Drozdowskyj1; Miguel A Molina1; Jose Antonio Lopez-Martin18; Alfonso Berrocal19 for the Spanish Melanoma Group (GEM). Intermittent BRAF inhibition in advanced BRAF mutated melanoma:  results of a phase II randomized trial. Nature communications 2021 2:7008 | https://doi.org/10.1038/s41467-021-26572-6
  17. Jeffrey Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel Tenney, Hao Tang, Georgina V. Long. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Stage IIIB–D or Stage IV Melanoma (CheckMate 915). J Clin Oncol. 2022; doi:10.1200/JCO.22.01770
  18. Paula Granado-Martinez, Elena González-Sánchez, Sara García Ortega, Kimberley McGrail, Rafael Selgas, Judit Grueso, Rosa Gil, Javier Hernandez-Losa, Berta Ferrer, Josep Villanueva, Olga Méndez, Sergio Espinosa-Gil, José M. Lizcano, Eva Muñoz-Couselo, Vicenç GarcíaPatos and Juan A. Recio. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Nature cancer/ Communications Biology 3, Article number: 366 (2020); DOI: 10.1038/s42003-020-1092-0
  19. Adriana Sánchez-Danés, Jean-Christophe Larsimont, Mélanie Liagre, Eva Muñoz-Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, Véronique del Marmol, Josep Tabernero & Cédric Blanpain A slow cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 562, 434-438 (2018). ISSN: 1476-4687. DOI: 10.1038/s41586-018-0603-3
  20. Juan Recio, Mileidys Pérez-Alea, Kimberley McGrail, Sara Sánchez-Redondo, Berta Ferrer, Guy Fournet, Javier Cortes, Eva Muñoz-Couselo, Javier Hernández, Stephan Tenbaum, Guillaume Martin, regis Costello, Ceylan Ismail, and Vicenç Garcia-Patos. ‘ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment’. Oncogene 2017, 1-14.
  21. Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M. ‘Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR’. Nat Med. 2015 Jul;21(7):741-50.
  22. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo Effector YAP promotes resistance to RAF and MEK targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.

Totes les publicacions

  1. Sergio Martinez-Recio1,2; Maria Alejandra Molina1, Eva Muñoz-Couselo3, Alberto R Sevillano-Tripero4, Francisco Aya5, Ana Arance5, Mayra Orrillo6, Juan Martin-Liberal6, Luis Fernandez-Morales7, Rocio Lesta8, Maria Quindos-Varela8, Maria Nieva9, Joana Vidal9, Daniel Martinez-Perez10, Andres Barba1 and Margarita Majem Adjuvant immunotherapy after resected melanoma: survival outcomes, prognostic factors and patterns of relapse. Cancers 2025, 17,143. https://doi.org/10.3390/cancers17010143
  2. Ainara Soria; Juan José Serrano Domingo; Pedro Sanchez Mauriño; Regina García Galindo; Silvia Sequero; Lourdes Gutiérrez Sanz; Guillermo Crespo; Roberto Díaz-Beveridge; Teresa Puértolas; Pedro López; Joaquín Fra Rodríguez; Rafael López Castro; Cristina Aguayo; Javier Valdivia; Alberto Jacobo Cunquero-Tomás; Gretel Benítez; Pablo Ayala de Miguel; Enrique Espinosa; Eva Muñoz-Couselo; Begoña Campos; Lourdes García Sánchez; Pablo Cerezuela. Real Life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial. Frontiers in Oncology. Volume 15 – 2025 | doi: 10.3389/fonc.2025.1466185
  3. Axel Hauschild¹, Paolo Antonio Ascierto², Ana Arance³ ⁴⁰, Nethanel Asher⁴, Kirill Baryshnikov⁵, Miguel-Angel Berciano-Guerrero⁶, Carola Berking⁷, Christian U. Blank⁸, Matteo S. Carlino⁹, Nina Dabelić¹⁰, Diwakar Davar¹¹, Lev Demidov⁵, Brigitte Dreno¹², Caroline Dutriaux¹³, Alexander Eggermont¹⁴ ⁷², Enrique Espinosa¹⁵, Andrea Forschner¹⁶ ⁸⁵, Ana-Maria Forsea¹⁷ ⁵⁵, Olivier Gaide¹⁸, Caroline Gaudy-Marqueste¹⁹, Iva Gavrilova²⁰, Christoffer Gebhardt²¹, Stephan Grabbe²², Ralf Gutzmer²³, Christine Hafner²⁴, Omid Hamid²⁵, Jessica Hassel²⁶, Christoph Hoeller²⁷, Celine Jacobs²⁸, Sekwon Jang²⁹, Katharina C. Kähler¹, Lidija Kandolf³⁰, Roland Kaufmann³¹, Helmut Kehrer³², John M. Kirkwood¹¹, Peter Koelblinger³⁴, Celeste Lebbé³⁵, Ulrike Leiter¹⁶, Evan J. Lipson³⁶, Elisabeth Livingstone³⁷, Georgina V. Long⁹ ³⁸, Jason J. Luke¹¹, Marcus Maia³⁹, Josep Malvehy³ ⁴⁰, Mario Mandalà⁴¹, Joanna Mangana⁴², Jasmina Marić Brozić¹⁰, Ivan Marquez Rodas⁴³, Salvador Martin-Algarra⁴⁴, Lara Valeska Maul⁴⁵, Laura Mazilu⁴⁶, Grant McArthur⁴⁷, Inderjit Mehmi²⁵, Friedegund Meier³³ ⁴⁸, Tanja Mesti⁴⁹, Tara C. Mitchell⁵⁰, Peter Mohr⁵¹, Justin Moyers²⁵, Eva Muñoz Couselo⁵², Yana G Najjar¹¹, Yasuhiro Nakamura⁵³, Bart Neyns⁵⁴, Janja Ocvirk⁴⁹, Kristina Orlova⁵, Bogdan Catalin Popescu⁵⁵, Aleksandar Popovic⁵⁶, Christian Posch⁵⁷, Paola Queirolo⁵⁸, Egle Ramelyte⁴², Erika Richtig⁵⁹, Caroline Robert⁶⁰, Rachel Roberts-Thomson⁶¹, Andrée Rorive⁶², Christina H. Ruhlmann⁶³, Annemie Rutten⁶⁴, April K. S. Salama⁶⁵, Igor Samoylenko⁵, Dirk Schadendorf³⁷, Bastian Schilling⁶⁶, Richard Scolyer³⁸, Gergana Shalamanova-Deleva⁶⁷, Marco Siano⁶⁸, James W. Smithy⁶⁹, Vernon K. Sondak⁷⁰, Philipp Stelzhammer²⁴, Eggert Stockfleth⁷¹, Karijn Suijkerbuijk¹⁴, Amina J. Suljevic⁸⁶, Patrick Terheyden⁷³, Alessandro A. E. Testori⁷⁴, Pawel Teterycz⁷⁵, Julia K. Tietze⁷⁶, Vincas Urbonas⁷⁷, Igor Utyashev⁷⁸, Astrid A. M. van der Veldt⁷⁹, Marcia Venter⁸⁰, Rupert Wegher⁸¹, Michael Weichenthal¹, Alberto Weinstein⁸², Hassane M. Zarour¹¹, Lisa Zimmer³⁷, Grigorii Zinovev⁸³, Paolo Nuti⁸⁴, Claus Garbe⁸⁵. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. Lancet Oncol 2025 Jan;26(1):12-14. doi: 10.1016/S1470-2045(24)00627-2.
  4. Eva Muñoz Couselo, Carola Berking, Jean François Baurain, Serena Martelli, Ramon Arntz, Paola Savoia. Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma. Journal of the American Academy of Dermatology 2025; http://doi.org/10.1111/jdv.20629
  5. Paolo A. Ascierto1,a, Hao Tang2,a, Sonia Dolfi2, Marta Nyakas3, Marie Inge Svane4, Eva Muñoz-Couselo5, Jean Jacques Grob6, Carlos Alberto GomezRoca7, Vanna Chiarion Sileni8, Katriina Peltola9, James Larkin10, Ignacio Melero11, Margaret Callahan12, Reinhard Dummer13, Patrick Djidel14, Deepti Warad2, Diane Reusser-Wolf14, Evan Lipson15,b, Charlie GarnettBenson2,b. Effect of prior treatment on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab + relatlimab therapy in patients with melanoma from RELATIVITY-020. Journal of ImmunoTherapy of Cancer (JITC) 2025, volume 13; DOI 1136/jitc-2024-009773
  6. Rebecca Dent,1 Javier Cortés,2,3,4 Yeon Hee Park,5 Eva Muñoz-Couselo,2,6 Sung-Bae Kim,7 Joohyuk Sohn,8 Seock-Ah Im,9 Esther Holgado,10 Theodoros Foukakis,11 Sherko Kümmel,12 Jennifer Yearley,13 Anran Wang,13 Michael Nebozhyn,13 Lingkang Huang,13 Razvan Cristescu,13 Petar Jelinic,13 Vassiliki Karantza,13 Peter Schmid. Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Breast Cancer Research (2025) 27:35; https://doi.org/10.1186/s13058-024-01946-y
  7. Eva Muñoz Couselo1, Ainara Soria Rivas2, Shahneen Sandhu3, Georgina V Long4, Miguel Fernández de Sanmamed Gutiérrez5, Anna Spreafico6, Wilson H Miller7, Elizabeth Buchbinder8, Mario Sznol9, Hans Prenen10, Alexander Fedenko11, Mohammed Milhem12, Ana María Arance Fernández13, Jean-Jacques Grob14, Lev Demidov15, Caroline Robert16, Svetlana Protsenko17, Christin Habigt18, Stefan Evers19, §, Nassim Sleiman19, David Dejardin19, Caroline Ardeshir20, Nicole Martin21, Christophe Bötsch19, Jehad Charo21, Volker Teichgräber19, Anton Kraxner19, Nino Keshelava21, Oliver Bechter22. Phase 1b study of the immunocytokine simlukafusp alfa (FAP-IL2v), in combination with pembrolizumab as treatment of advanced and/or metastatic melanoma. Cancer Res Commun. 2025 Feb 1;5(2): 358-368.doi: 10.1158/2767-9764.CRC-24-0601
  8. Reinhard Dummer1, Shahneen Sandhu2, Wilson H. Miller3, Marcus O. Butler4, Matthew R.J. Taylor5, Lucie Heinzerling6, Christian U. Blank7, Eva Muñoz Couselo8, Howard A. Burris 3rd9, Michael A. Postow10, Bartosz Chmielowski11, Mark R. Middleton12, Carola Berking13, Jessica C. Hassel14, Anja Heike Gesierich15, Cornelia Mauch16, Joseph F Kleha17, Anna Polli18, Allison S. Harney19, Alessandra di Pietro18, Paolo Ascierto20. Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAF V600-Mutant Metastatic Melanoma. Clin Cancer Res (2025) https://doi.org/10.1158/1078-0432.CCR-24-0254
  9. Juan José Serrano Domingo 1, Pedro Sanchez Mauriño 2, Regina García Galindo 3, Silvia Sequero 4, Lourdes Gutiérrez Sanz 5, Guillermo Crespo 6, Roberto Díaz-Beveridge 7, Teresa Puértolas 8, Pedro López 9, Joaquín Fra Rodríguez 10, Rafael López Castro 11, Cristina Aguayo 12, Javier Valdivia 13, Alberto Cunquero-Tomás 14, Gretel Benítez 15, Pablo Ayala de Miguel 16, Enrique Espinosa 17, Eva Muñoz-Couselo 18, Begoña Campos 19, Pablo Cerezuela-Fuentes 20. Real Life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial. Oncol.Sec. Skin Cancer Volume 15 – 2025 | doi: 10.3389/fonc.2025.1466185
  10. Pablo Cerezuela7; Maria Gonzalez-Cao1; Teresa Puertolas2; Jose Luis Manzano3; Cayetana Maldonado4; Oriol Yelamos5; Miguel A Berciano-Guerrero6; Juan Martin-Liberal8; Eva Muñoz-Couselo9; Enrique Espinosa10-11; Ana Drozdowskyj1; Alfonso Berrocal12; Ainara Soria13; Ivan Marquez-Rodas14; Salvador Martin-Algarra15; Maria Quindos16; Susana Puig11,17 for the Spanish Melanoma Group (GEM). Access to systemic treatment of Non-Melanoma Skin Cancer in Spain: A Survey Analysis. Frontiers of oncology Volume 27,  386–391, (2025)
  11. Kimberley McGrail, 1 Paula Granado-Martínez, 1 Roberto Orsenigo, 2 Ginevra Caratù,3 Paula Nieto, 2 Holger Heyn, 3 Berta Ferrer, 3 Javier Hernández-Losa, 4 Eva Muñoz-Couselo, 14 5 Vicenç García-Patos and 1 15 *Juan A. Recio. Transcriptional reprogramming induced by neonatal UV radiation prevents BRAFV600E 5 -induced growth arrest in melanocytes. Oncogene 2025; https://doi.org/10.1038/s41388-025-03339-7
  12. Martín-Lluesma1,2*, U. Dafni3,4*, †, K. Vervita5, D. Karlis6, G. Dimopoulou5, Z. Tsourti5, E. Politi5, G. Villacampa1, V. Galvao1, J. Lostes1, E. Muñoz-Couselo1, M. Rotxés1, X. Villalobos1, S. Muñoz1, J.B.A.G. Haanen7,8,9, I.M. Svane10, J.M. Piulats11, J.M. Liberal11, A. Gros1, G. Coukos12, E. Garralda1. Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology, 2025; DOI: 10.1016/j.annonc.2025.04.001
  13. Michael Weichenthal a, Eva Ellebaek b, Joanna Mangana c, Nethanel Asher d, Iva Gavrilova e, Lidija Kandolf f, Selma Ugurel g, Axel Hausschild a, Friedegund Meier h, Ulrike Leiter i, Elisabeth Livingstone g, Christoffer Gebhardt j, Ralf Gutzmer k, ChristinaH. Ruhlmann l, Louise MahnckeGuldbrandt m, CharlotteA. Haslund n, Sylwia Kopec o, Paweł Teterycz p, Marc Bender q, Wilfried Poudroux r, Eva MuñozCouselo s, MiguelAngel BercianoGuerrero t, Gergana Shalamanova u, DanielleK. DePalo v, JasminaMarić Brozić w, Vanna ChiarionSileni x, Anna Arance y, Dimitrios Ziogas z, Caroline Robert aa, AnthonieObik vandeVelde ab, AwaAminata Gassama ac, Ronnie Shapira ad, Guy BenBetzalel ad, Shirly Grynberg ad, Egle Ramelyte c, Fabio Bertoldo c, Valerio DelPrete c, Caroline GaudyMarqueste ae, Peter Mohr af, Reinhard Dummer c, PaoloA. Ascierto ag, Helen Gogas z, Enrique Espinosa ah, Celeste Lebbé ai, Piotr Rutkowski o, John Haanen aj, Dirk Schadendorf g, IngeMarie Svane b, EUMelaReg Consortium Members 1. Immune Checkpoint Inhibition in Metastatic or Non-resectable Melanoma after Failure of Adjuvant anti-PD1 treatment. A EUMelaReg Real-world Evidence study. European Journal of cancer Volume 220, 2 May 2025, 115339
  14. Reinhard Dummer, Shahneen Sandhu, Wilson Miller, Marcus Butler, Matthew Taylor, Lucie Heinzerling, Christian Blank, Eva Muñoz-Couselo, Howard Burris, Michael Postow, Bartosz Chmielowski, Mark Middleton, Carola Berking, Jessica Hassel, Anja Gesierich, Cornelia Mauch, Joseph Kleha, Anna Polli, Allison Harney, Alessandra di Pietro, and Paolo Ascierto.  Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAF V600-Mutant Metastatic Melanoma. Clinical Cancer Research 2025; https://doi.org/10.1158/1078-0432.CCR-24-0254
  15. Caroline Robert, Michal Kicinski, Caroline Dutriaux, Émilie Routier, Anne-Sophie Govaerts, Emanuel Bührer, Eve-Marie Neidhardt, Xavier Durando, Barouyr Baroudjian, Philippe Saiag, Caroline Gaudy-Marqueste, Paolo A. Ascierto, Ana Arance, Michelangelo Russillo, Jean-Luc Perrot, Laurent Mortier, Francois Aubin, Stéphane Dalle, Florent Grange, Eva Muñoz-Couselo, Bordeaux second author, Centre Léon Bérard second author, Auvergne second author, Céleste Lebbe, Boulogne second author, Alexander M.M. Eggermont, Felix Oppong, Leen Wijnen, Bastian Schilling, Mario Mandalà*, Paul Lorigan*, Alexander C.J. van Akkooi*. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K melanoma (EBIN): an international randomized phase II study. Lancet Oncology 2025, Volume 26, Issue 6, June 2025, 781-794. https://doi.org/10.1016/S1470-2045(25)00133-0
  16. Mario Mandalà1*, Teresa Amaral2*, Piotr Rutkowski3*, Maria Chiara Sergi4, Marie-Lena Rasch 2, Naima Benannoune5, Patricio Serra6, Maria Grazia Vitale7, Diana Giannarelli8, Ana Maria Arance9, Eva Munoz Couselo10, Bart Neyns11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan6 , Georgina V. Long22, Caroline Robert24§, Paolo A. Ascierto7§. Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study. European Journal of cancer 2025
  17. Michael K. Wong, M.D., Ph.D., F.R.C.P.C,1*, †, Mohammed M. Milhem, M.B., B.S.2*, Joseph J. Sacco, Ph.D., F.R.C.P.3, Judith Michels, M.D., Ph.D.4, Gino K. In, M.D.5, Eva Muñoz Couselo, M.D., Ph.D.6, Dirk Schadendorf, M.D.7, Georgia M. Beasley, M.D.8, Jiaxin Niu, M.D., Ph.D.9, Bartosz Chmielowski, M.D., Ph.D.10, Trisha M. Wise-Draper, M.D., Ph.D.11, Tawnya Lynn Bowles, M.D.12, Katy K. Tsai, M.D.13, Céleste Lebbé, M.D., Ph.D.14, Caroline Gaudy-Marqueste, M.D., Ph.D.15, Mark R. Middleton, M.D.16, Adel Samson, Ph.D.17, Jason A. Chesney, M.D., Ph.D.18, Ari M. VanderWalde, M.D.19, Yousef Zakharia, M.D.2, Kevin J. Harrington, Ph.D.20, Elizabeth Appleton20, Praveen K. Bommareddy, Ph.D.21, Junhong Zhu, Ph.D.21, Marcus Viana, M.D.21, Jeannie W. Hou, M.D.21, Robert S. Coffin, Ph.D.21, Caroline Robert, M.D., Ph.D.22 RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma. Journal of Clinical Oncology (JCO) 0, 10.1200/JCO-25-01346 2025; https://doi.org/10.1200/JCO-25-01346
  18. Eva Muñoz Couselo, Carola Berking, Jean François Baurain, Serena Martelli, Ramon Arntz, Paola Savoia. Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma.  J Eur Acad Dermatol Venereol, 39: e788-e790. https://doi.org/10.1111/jdv.20629
  19. Georgina Long1–3,*, Nitya Nair4,*, Daniel Marbach4, Richard Scolyer1,2,5, Sabine Wilson6, Denise Cotting4, Nicolas Staedler4, Rodabe Amaria7, Paolo Ascierto8, Ahmed Tarhini9, Caroline Robert10, Omid Hamid11, Caroline Gaudy12, Celeste Lebbe13, Eva Munoz-Couselo14, Alex Menzies1–3, Cecile 15, Giuseppe Curigliano16, Mario Mandala17, Nikki Jessop4, Uwe Bader4, Maurizio Perdicchio4, Volker Teichgraeber4, Merlind Muecke4, Christian Blank18,†, Christoph Markert19,†. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody alone and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase Ib/II Morpheus-Melanoma trial. Nat Med(2025). https://doi.org/10.1038/s41591-025-03967-2
  20. Clara Mayo de las Casas1,2*, Eloisa Jantus-Lewintre3*, Sebastian Ortiz Reina5, Ana Drozdowskyj1, Pablo Cerezuela6, Jose Luis Manzano7, Pablo Ayala de Miguel8, Ana Arance Fernandez9, Miguel Angel Berciano Guerrero10, Almudena Garcia Castano11, Teresa Puertolas12, Guillermo Crespo13, Maria Quindos-Varela14, Juan Francisco Rodriguez-Moreno15, Alfonso Berrocal16, Eva Muñoz-Couselo17, Enrique Espinosa18, Silvia Calabuig-Fariñas4, Miguel Angel Molina1,2, Rafael Rosell1,2, Joan Anton Puig-Butille4**, Maria Gonzalez-Cao1** , on behalf of the Spanish Melanoma Group (GEM). Cross-method comparison for BRAF p.V600 Mutation cfDNA Testing in Melanoma: BRAFI study. EJD skin cancer 2025; https://doi.org/10.1016/j.ejcskn.2025.100738
  21. Pablo Cerezuela-Fuentes, Carlos Aguado de la Rosa; Guillermo Crespo; Miguel-Ángel Berciano-Guerrero; Ainara Soria; Eva Muñoz-Couselo; Rafael López Castro; Margarita Majem; Pablo Ayala de Miguel; José Luis Manzano; Lorena Bellido; Mª José Lecumberri; Mónica Corral Subias; José Carlos Villa Guzmán; Berta Hernández; Enrique Espinosa; Teresa Puértolas; Lourdes Gutiérrez Sanz; Javier Medina Martínez; Vicente Palomar Abril; Salvador Martín Algarra; Iván Márquez-Rodas. Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study. Melanoma Research 2025 sep 3; PMID: 40901826; DOI: 1097/CMR.0000000000001062
  22. Georgina Long1–3,*, Nitya Nair4, *, Daniel Marbach4, Richard Scolyer1,2,5, Sabine Wilson6, Denise Cotting4, Nicolas Staedler4, Rodabe Amaria7, Paolo Ascierto8, Ahmed Tarhini9, Caroline Robert10, Omid Hamid11, Caroline Gaudy12, Celeste Lebbe13, Eva Munoz-Couselo14, Alex Menzies1–3, Cecile 15, Giuseppe Curigliano16, Mario Mandala17, Nikki Jessop4, Uwe Bader4, Maurizio Perdicchio4, Volker Teichgraeber4, Merlind Muecke4, Christian Blank18,†, Christoph Markert19,†. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody alone and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase Ib/II Morpheus-Melanoma trial. Nat Med(2025). https://doi.org/10.1038/s41591-025-03967-2
  23. Rodrigo Dienstmann1,2, Ana Vivancos1, Paolo Nuciforo1, Susana Aguilar1, Fiorella Ruiz-Pace1, Cristina Viaplana1, Jenifer Gonzalez1, Benet Fite1, Anna Pedrola1, Elena Elez3, Cristina Saura3, Enriqueta Felip3, Teresa Macarulla3, Jaume Capdevila3, Ana Oaknin3, Joan Carles3, Joaquin Mateo1,3, Eva Muñoz-Couselo3, Judith Balmaña3, Irene Braña3, Elena Garralda3, Josep Tabernero1,2,3,4,5. Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. ESMO open 2025; https://doi.org/10.1016/j.esmoop.2025.105888
  24. Enrique Espinosa1, Miguel-Ángel Berciano-Guerrero2, Eva Muñoz-Couselo3, Teresa Puértolas4, José Luis Manzano5, Ainara Soria6, Pablo Ayala de Miguel7, Guillermo Crespo8, Lourdes Gutiérrez Sanz9, Pablo Cerezuela-Fuentes10, Carlos Aguado de la Rosa11, Margarita Majem12, Almudena García Castaño13, Alfonso Berrocal14, Francisco Ramon García Arroyo15, María Rodríguez de la Borbolla16, Lorena Bellido17, Javier Medina Martínez18, Luis Antonio Fernández19, Alfonso Martin Carnicero20, Rafael López Castro21, Aida Bujosa Rodríguez22, Mª José Lecumberri23, José Carlos Villa Guzmán24, Begoña Campos Balea25, Joaquín Fra Rodríguez26, Javier Valdivia Bautista27, Victor Navarro Pérez28, Karmele Mujika29, Mónica Corral Subias30, Berta Hernández31, Salvador Martín Algarra32, Iván Márquez-Rodas33. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study GEM-1801. Clinical and Translational Oncology 2025, https://doi.org/10.1007/s12094-025-04098-3
  25. Georgina V. Long, Charlie Garnett-Benson, Sonia Dolfi, Paolo Ascierto, Jun Guo, Ahmed Tarhini, Sunandana Chandra, Eva Munoz-Couselo, Michele Del Vecchio, Andreia Cristina de Meio, Margaret Callahan, Helen Gogas, Reinhard Dummer, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereaux, Ioannis Thomas, Annie Yu, Andrew Fisher, Patrick Djidel, Armand Chouzy, Mark Semaan, Bohang Chen, Alicia Cheong, Bonnie Wang, Hussein Tawbi. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med(2025).; https://doi.org/10.1038/s41591-025-04032-8
  26. Elena Garralda , Dr charles Abbott , Alma Calahorro , Oriol Mirallas , Jason Pugh , Ms Ana Moreno , Dr Kathleen Keough , Vladimir Galvao , Dr Guzman Alonso , Armando Olano , Maria Vieito , Arjun Oberoi , Julia Lostes Bardaji , Alberto Hernando-Calvo , Dr Irene Braña , Giulia Pretelli , Belen Ortega , Ms Carlota Arenillas , Natalia Czerniak , Fabio Navarro , Bailiang Li , Dr Rachel Pyke , Neeraja Ravi , Christina Zatse , Francesco Grussu , Marta Sanz , Cristina Viaplana , Kira Raskina , Mr Jose Jimenez , Roberta Fasani , Patricia Casbas-Hernandez , Ezoglin Oflazoglu , Darren Hodgson , Jorge Reis-Filho , Enriqueta Felip , Dr Elena Elez , Eva Muñoz-Couselo , Dr Rodrigo Dienstmann , Professor Josep Tabernero , Dr Raquel Perez , Paolo Nuciforo , Dr Richard Chen , Sean Michael Boyle. Broad utility of ultrasensitive analysis of ctDNA dynamics across solid tumors treated with immunotherapy. Clin Cancer Res2025, OF1–OF17. https://doi.org/10.1158/1078-0432.CCR-25-2312
  27. Pablo Cerezuela-Fuentes 1#*, Antonio Piñero-Madrona 2#, Eva Muñoz-Couselo 3, José Luis Manzano 4, Miguel-Ángel Berciano-Guerrero 5, Margarita Majem 6, Enrique Espinosa 7, Ainara Soria 8, Pablo Ayala de Miguel 9, Almudena García Castaño 10, Guillermo Crespo 11, Lourdes Gutiérrez Sanz 12, Carlos Aguado de la Rosa 13, Luis Antonio Fernández-Morales 14, Teresa Puértolas 15, Joaquín Fra Rodríguez 16, María Rodríguez de la Borbolla 17, Lorena Bellido 18, Rafael López Castro 19, Eduardo Castañón 20, Victor Navarro Pérez 21, Francisco Ramon García Arroyo 22, José Carlos Villa Guzmán 23, Begoña Campos Balea 24, Berta Hernández 25, Salvador Martín Algarra 20, Iván Márquez-Rodas 26. Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clin Transl Oncol. 2025 Dec 20. doi: 10.1007/s12094-025-04164-w.
  28. Cañueto J, Muñoz-Couselo E, Cardona-Machado C, Becerril-Andrés S, Martín-Vallejo J, Serra-Guillén C, Soria A, Serrano-Domingo JJ, Ortiz-Velez C, Lostes J, García-Castaño A, Puig S, Fernández de Misa R, Medina J, Aguado C, Ayala de Miguel P, Navarro-Navarro I, Masferrer E, Delgado M, Bellido-Hernández L, Sanmartin O. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data. J Eur Acad Dermatol Venereol. 2024 Aug;38(8):e666-e670. doi: 10.1111/jdv.19821.
  29. Clavero-Rovira L, Gómez-Tomás Á, Bassas-Freixas P, Bodet D, Ferrer B, Hernández-Losa J, Muñoz-Couselo E, Pérez-Benavente A, García-Patos V, Ferrándiz-Pulido C. Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study. Cancers (Basel). 2024 Jan 3;16(1):227. doi: 10.3390/cancers16010227.
  30. Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Eur J Cancer. 2024 Mar;199:113542. doi: 10.1016/j.ejca.2024.113542.
  31. Riveiro-Barciela M, Barreira-Díaz A, Salcedo MT, Callejo-Pérez A, Muñoz-Couselo E, Iranzo P, Ortiz-Velez C, Cedrés S, Díaz-Mejía N, Ruiz-Cobo JC, Morales R, Aguilar-Company J, Zamora E, Oliveira M, Sanz-Martínez MT, Viladomiu L, Martínez-Gallo M, Felip E, Buti M. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury. Aliment Pharmacol Ther. 2024 Apr;59(7):865-876. doi: 10.1111/apt.17898.
  32. Spreafico A, Couselo EM, Irmisch A, Bessa J, Au-Yeung G, Bechter O, Svane IM, Sanmamed MF, Gambardella V, McKean M, Callahan M, Dummer R, Klein C, Umaña P, Justies N, Heil F, Fahrni L, Opolka-Hoffmann E, Waldhauer I, Bleul C, Staack RF, Karanikas V, Fowler S. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. Front Oncol. 2024 Mar 21;14:1346502. doi: 10.3389/fonc.2024.1346502.
  33. Remon J, Auclin E, Zubiri L, Schneider S, Rodriguez-Abreu D, Minatta N, Gautschi O, Aboubakar F, Muñoz-Couselo E, Pierret T, Rothschild SI, Cortiula F, Reynolds KL, Thibault C, Gavralidis A, Blais N, Barlesi F, Planchard D, Besse BMD. Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort. ESMO Open. 2024 May;9(5):103004. doi: 10.1016/j.esmoop.2024.103004.
  34. Márquez-Rodas I, Muñoz Couselo E, Rodríguez Moreno JF, Arance Fernández AM, Berciano Guerrero MÁ, Campos Balea B, de la Cruz Merino L, Espinosa Arranz E, García Castaño A, Berrocal Jaime A. SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clin Transl Oncol. 2024 Nov;26(11):2841-2855. doi: 10.1007/s12094-024-03497-2.
  35. McGrail K, González-Sánchez E, Granado-Martínez P, Orsenigo R, Ding Y, Ferrer B, Hernández-Losa J, Ortega I, Martín-Caballero J, Muñoz-Couselo E, García-Patos V, Recio JA. Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation. Mol Oncol. 2025 Feb;19(2):329-343. doi: 10.1002/1878-0261.13715.
  36. Gonzalez-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MÁ, Cerezuela P, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S; Spanish Melanoma Group (GEM). Access to melanoma drugs in Spain: a cross-sectional survey. Clin Transl Oncol. 2024 Oct;26(10):2572-2583. doi: 10.1007/s12094-024-03501-9.
  37. Gogas H, Ravimohan S, Datta A, Chhibber A, Couselo EM, Diab A, Pereira C, Quéreux G, Sandhu S, Curti B, Khushalani NI, Taylor MH, Daniels GA, Spreafico A, Meniawy T, Van Den Eertwegh AJM, Sun Y, Arriaga Y, Zhou M, Long GV, Lebbé C. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab. NPJ Precis Oncol. 2024 Jul 19;8(1):150. doi: 10.1038/s41698-024-00641-7.
  38. Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol. 2025 Jan;92(1):68-77. doi: 10.1016/j.jaad.2024.06.108. Epub 2024 Sep 7.
  39. Usset J, Rosendahl Huber A, Andrianova MA, Batlle E, Carles J, Cuppen E, Elez E, Felip E, Gómez-Rey M, Lo Giacco D, Martinez-Jimenez F, Muñoz-Couselo E, Siu LL, Tabernero J, Vivancos A, Muiños F, Gonzalez-Perez A, Lopez-Bigas N. Five latent factors underlie response to immunotherapy. Nat Genet. 2024 Oct;56(10):2112-2120. doi: 10.1038/s41588-024-01899-0.
  40. Cohen G, Rapoport B, Chan SW, Ruff P, Arance A, Mujika Eizmendi K, Houghton B, Brown MP, Zielinski RM, Muñoz Couselo E, Lyle M, Anderson JR, Jain L, de Alwis D, Lala M, Akala O, Chartash E, Jacobs C. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PLoS One. 2024 Nov 12;19(11):e0309778. doi: 10.1371/journal.pone.0309778.
  41. Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michielin O, Ascierto PA; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Jan;36(1):10-30. doi: 10.1016/j.annonc.2024.11.006. Epub 2024 Nov 14.
  42. Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, Munoz-Couselo E, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA. Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma. Clin Cancer Res. 2025 Mar 19. doi: 10.1158/1078-0432.CCR-24-0254. Epub ahead of print.
  43. Wong SK, Blum SM, Sun X, Da Silva IP, Zubiri L, Ye F, Bai K, Zhang K, Ugurel S, Zimmer L, Livingstone E, Schadendorf D, Serra-Bellver P, Muñoz-Couselo E, Ortiz C, Lostes J, Huertas RM, Arance A, Pickering L, Long GV, Carlino MS, Buchbinder EI, Vázquez-Cortés L, Jara-Casas D, Márquez-Rodas I, González-Espinoza IR, Balko JM, Menzies AM, Sullivan RJ, Johnson DB. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. Eur J Cancer. 2023 Mar;181:188-197.
  44. Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265.
  45. de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. J Clin Oncol. 2023 May 10;41(14):2651-2660.
  46. Gonzalez-Cao M, Puertolas T, Martinez-Vila C, Carrera C, Maldonado Seral C, Rodríguez-Jiménez P, Sequero S, Cerezuela-Fuentes P, Feltes Ochoa R, Muñoz E, Antoñanzas Basa M, Martín-Liberal J, Soria A, Francisco Rodriguez Moreno J, Marquez-Rodas I, Lopez Criado P, Luis Manzano J, Lopez-Castro R, Ayala de Miguel P, Villalobos L, Martin Algarra S, Gonzalez-Barrallo I, Boada A, García Castaño A, Puig S, Crespo G, Luna Fra P, Aguayo Zamora C, Feito Rodríguez M, Valles L, Drozdowskyj A, Gardeazabal J, Antonio Fernandez-Morales L, Rodrigo A, Cruz R, Yelamos O, Rubio B, Mujica K, Provencio M, Berrocal A; Spanish Melanoma Group (GEM). SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. Clin Transl Oncol. 2023 Mar;25(3):768-775.
  47. Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Galceran JC, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. 2023 Oct 13;4(10):710-727.e5. d
  48. Riveiro-Barciela M, Barreira-Díaz A, Callejo-Pérez A, Muñoz-Couselo E, Díaz-Mejía N, Díaz-González Á, Londoño MC, Salcedo MT, Buti M. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. Clin Gastroenterol Hepatol. 2023 Mar;21(3):732-740.
  49. Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, Sznol M, Franke F, Ciuleanu TE, Pereira C, Muñoz Couselo E, Bronzon Damian F, Schenker M, Perfetti A, Lebbe C, Quéreux G, Meier F, Curti BD, Rojas C, Arriaga Y, Yang H, Zhou M, Ravimohan S, Statkevich P, Tagliaferri MA, Khushalani NI. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. J Clin Oncol. 2023 Oct 20;41(30):4756-4767.
  50. Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR, Mant A, Sharma V, Shue H, Tazbirkova A, Berciano-Guerrero MA, Charoentum C, Dalle S, Dechaphunkul A, Dudnichenko O, Koralewski P, Lugowska I, Montaudié H, Muñoz-Couselo E, Sriuranpong V, Oliviero J, Desai J. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023 Oct;11(10):e007637.
  51. Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, Arance AM, Grange F, Meyer N, Joshi AJ, Billan S, Hughes BGM, Grob JJ, Ramakrishnan K, Ge J, Gumuscu B, Swaby RF, Gutzmer R. Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629. Dermatol Ther (Heidelb). 2023 Dec;13(12):3165-3180.
  52. Schmid P, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia JA, Zhou X, Haiderali A, Nguyen AM, Cortes J, Winer EP. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. Eur J Cancer. 2023 Dec;195:113393.
  53. Muñoz E et al. ‘A rare case of malignant solitary fibrous tumor of the spinal cord’. Spine. 2008 May 20; 33(12): E397-9.
  54. Muñoz E, Cedrés S, Felip E. ‘Rare tumors of the chest’. European Joruinal of cancer, 2009 Sep;45 Suppl 1:400-1.
  55. J. Pérez-García, E. Muñoz, N. Mulet, I. Núñez, M. Bellet, P. Gómez. ‘Rápida resolución de una púrpura trombótica trombocitopénica con quimioterapia y trastuzumab’. Casos clínicos en Cáncer de Mama. Módulo 1. Enero 2010.
  56. C. Suárez, R. Morales, E. Muñoz, J. Rodón, CM. Valverde and Joan Carles. Molecular basis for the treatment of renal cell carcinoma. Clinical and translational Oncology. Number 12. Volume 1. 2010.
  57. J. Carles Galcerán, E. Muñoz Couselo, C. Suarez Rodríguez, C. Valverde Morales. Cáncer de próstata: tratamiento intermitente con docetaxel. Rev. Cancer. Vol. 24 supl.1.pp 27-28, 2010.
  58. Del Campo J, Muñoz-Couselo E, Isabel Diaz-Corcuera, Ana Oaknin. Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer. Expert review of Anti-infective therapy, 2010 Jun;10(6):795-805. doi: 10.1586/era.10.59
  59. Alsina M, Ruiz-Echarri M, Capdevila J, Muñoz E, Tabernero JM. Biomarkers for therapies directed at angiogenesis. Current Colorectal Cancer Reports. 2010 Jun; 6 (3): 133-143
  60. Susana Cedres, Isabela Quispe, Pablo Martinez, Maria Longo, Eva Rodriguez, Cesar Serrano, Eva Muñoz, Esther Pallisa, Enriqeuta Felip. Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC). Clin Tansl Oncol 2010 Dec;12(12):829-35. doi: 10.1007/s12094-010-0605-6
  61. Javier Cortes, Crsitina Saura, Meritxell Bellet, Eva Muñoz-Couselo, Natalia Ramirez-Merino, Virgina Clavo, Jose Perez, Mari Vidal. HER2 and hormone receptor-positive breast cancer–blocking the right target. Nat Rev Clin Oncol. 2011 May;8(5):307-11. doi: 10.1038/nrclinonc.2010.185. Epub 2010 Dec 14
  62. Pérez Garcia J, Muñoz E, Cortes J. Role of antiangiogénesis in triple-negative breast cancer tumors. Cancer and chemotherapy reviews (6): 23- 29. Abril 2011.
  63. E. Muñoz-Couselo, J Perez-Garcia, J Cortes. Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. OncoTargets and Therapy. November 2011. Volume 2011:4 Pages 185 – 192
  64. Cortes, J., V. Calvo, N. Ramírez-Merino, J. O’Shaughnessy, A. Brufsky, N. Robert, M. Vidal, E. Muñoz, J. Perez, S. Dawood, C. Saura, S. Di Cosimo, A. González-Martín, M. Bellet, O.E Silva, D. Miles, A. Llombart and J. Baselga. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol, 2019 Jul 1;30(7):1179. doi: 10.1093/annonc/mdy535.
  65. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2019 Jul 1;30(7):1178. doi: 10.1093/annonc/mdy534.
  66. Pérez-García, JM. Muñoz-Couselo, E. Ortega, V. Cortés, J. The beautifyl story of pertuzumab. Expert Rev. Anticancer Ther. 12(6), 703-705, 2012.
  67. M. Oliveira, J. Cortés, M. Bellet, J. Balmaña, L. De Mattos-Arruda, P. Gómez, E. Muñoz, V. Ortega, J. Pérez, C. Saura, M. Vidal, I.T. Rubio, S. Di Cosimo. Management of the axilla in early breast cancer patients in the genomic era. Annals of Oncology 00: 1–8, 2012.
  68. Perez-Garcia J, Muñoz-Couselo E, Cortes J. The effect of biology in the treatment of small breast tumours. Am Soc Clin Oncol Educ Book 2013: 2013:25-31.
  69. Jose Perez-Garcia, Eva Muñoz-Couselo, Javier Cortes. Bone metastases: Causes, consequences and therapeutic opportunities. EJC SUPPLEMENTS 11 (2013) 254 – 256.
  70. Perez-Garcia J, Muñoz-Couselo E, Cortes J, Scaltriti M. Therapeutic antibodies in breast cancer. Seminars in oncology 41:576-588. October 2014.
  71. Zamora, E., Munõz-Couselo, E., Cortes, J., Perez-Garcia, J. The fibroblast growth factor receptor: A new potential target for the treatment of breast cancer. Current Breast Cancer Reports 2014, 6 (2), pp. 51
  72. Berrocal, Alfonso; Arance, Ana; Lopez Martin, Jose Antonio; Soriano, Virtudes; Muñoz, Eva; Alonso, Lorenzo; Espinosa, Enrique; Lopez Criado, Pilar; Valdivia, Javier; Martin Algarra, Salvador. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Melanoma Research, 2014 Dec; 24(6): 577–583.
  73. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo Effector YAP promotes resistance to RAF and MEK targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
  74. Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M. ‘Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR’. Nat Med. 2015 Jul;21(7):741-50.
  75. Eva Muñoz-Couselo, Jesús Soberino, José Manuel Pérez-García, Vanesa Ortega and Javier Cortés. ‘Recent advances in the treatment of melanoma with BRAF and MEK inhibitors’. Ann Transl Med 2015 Sep;3(15):207. doi: 10.3978/j.issn.2305-5839.2015.05.13.
  76. Maria Gonzalez-Cao, Clara Mayo-de-las-Casas, Miguel A. Molina-Vila, Leticia De Mattos-Arruda, Eva Muñoz-Couselo, Jose L. Manzano, Javier Cortes, Jose P. Berros, Ana Drozdowskyj, Miguel Sanmamed, Alvaro Gonzalez, Carlos Alvarez, Santiago Viteri, Niki Karachaliou, Salvador Martin Algarra, Jordi Bertran-Alamillo, Nuria Jordana-Ariza and Rafael Rosell. ‘BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors’. Melanoma Res 2015 Dec;25(6):486-95. doi: 10.1097/CMR.0000000000000187.
  77. Vivancos, Ana; Caratú, Ginevra; Matito, Judit; Muñoz-Couselo, Eva; Ferrer, Berta; Hernandez-Losa, Javier; Bodet, Domingo; Pérez-Alea, Mileidys; Cortés, Javier; García-Patos, Vincenç; Recio, Juan. ‘Genetic Evolution of Nevus of Ota Reveals Clonal Heterogeneity Acquiring BAP1 and TP53 Mutations’. Pigment Cell Melanoma Res 2016 Mar;29(2):247-53. doi: 10.1111/pcmr.12452.
  78. Mileidys Pérez-Alea, Ana Vivancos, Ginevra Caratú, Judit Matito, Berta Ferrer, Javier Hernandez-Losa, Javier Cortés, Eva Muñoz, Vicente Garcia-Patos, Juan A. Recio. ‘Genetic Profile of GNAQ-Mutated Blue Melanocytic Neoplasms Reveals Mutations in Genes Linked to Genomic Instability and the PI3K Pathway’. Oncotarget 2016 May 10;7(19):28086-95
  79. M. González-Cao, A. Arance, J. M. Piulats, I. Marquez-Rodas, J. L. Manzano, A. Berrocal, G. Crespo, D. Rodriguez, E. Perez-Ruiz, M. Berciano, A. Soria, A. G. Castano, E. Espinosa, C. Montagut, L. Alonso, T. Puertolas, C. Aguado, M. A. Royo, R. Blanco, J. F. Rodríguez, E. Muñoz, P. Mut, F. Barron, S. Martin-Algarra. ‘Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program’. Clinical and translational oncology. January 2017.
  80. Juan Recio, Mileidys Pérez-Alea, Kimberley McGrail, Sara Sánchez-Redondo, Berta Ferrer, Guy Fournet, Javier Cortes, Eva Muñoz-Couselo, Javier Hernández, Stephan Tenbaum, Guillaume Martin, regis Costello, Ceylan Ismail, and Vicenç Garcia-Patos. ‘ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment’. Oncogene 2017, 1-14.
  81. Muñoz-Couselo E, Zamora Adelantado E, Ortiz C, Soberino Garcia J, Perez-Garcia J. ‘NRAS-mutant melanoma: current challenges and future prospect’. Onco Targets Ther. 2017 Aug 8; 10:3941-3947. doi: 10.2147/OTT.S117121.
  82. J. Perez-Garcia, E. Munoz-Couselo, J. Soberino, F. Racca, J. Cortes. ‘Targeting the FGFR pathway in breast cancer’. The breast 37 (2018) 126-133.
  83. Maria Gonzalez-Cao, Clara Mayo de las Casas, Nuria Jordana Ariza, Jose Luis Manzano, Miguel Ángel Molina-Vila, Virtudes Soriano, Teresa Puertolas, Ariadna Balada, Ainara Soria, Margarita Majem, Clara Montagut, Eva Muñoz-Couselo, Delvys Rodríguez, Elizabeth Perej, Almudena Garcia, Javier Cortes, Ana Drozdowskyj, Niki Karachaliou, and Rafael Rosella, on behalf of the Spanish Melanoma Group. ‘Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy’.’ Melanoma Res 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.
  84. Mr. Azad Saei, Dr. Marta Palafox, Prof. Touati Benoukraf , Ms. Nishi Kumari , Mr. Patrick William Jaynes , Dr. Prasanna Vasudevan Iyengar , Dr. Eva Muñoz-Couselo , Dr. Paolo Nucifero , Dr. Javier Cortés , Mr. Christopher Notzel , Dr. Nesaretnam Barr Kumarakulasinghe , Dr. John Lalith Charles Richard , Mr. Zul Fazreen Bin Adam Isa , Dr. Brendan Pang , Mrs. Marta Guzman , Dr. Zhou Siqin , Dr. Henry Yang , Dr. Wai Leong Tam , Dr. Violeta Serra. ‘Loss of USP28 mediated BRAF degradation drives resistance to RAF cancer therapies’. JEM 07-02-2018 issue, vol. 215 no. 7.
  85. Gerard Oristrell, Jordia Bañeras, Javier Ros, Eva Muñoz-Couselo. ‘Cardiac tamponade and adrenal insufficiency due to pembrolizumab. A case report’. Eur Heart J Case Rep, Apr 3;2(2): yty038. doi: 10.1093/ehjcr/yty038. eCollection 2018 Jun.
  86. Alejandro Garcia-Alvarez, Alberto Hernando, Fabiola Amair-Pineda and Eva Muñoz Couselo. Management of Severe Colitis in the Setting of Experimental Immunotherapy Combination. J Tumor Med Prev. Volume 3 Issue 1 – April 2018. DOI:10.19080/JTMP.2018.03.55560
  87. Eva Muñoz, Mauricio Lema, José Luis Manzano. Highlights ASCO 2018. Revista cáncer de piel. Volumen 1, número 0-2018. ISSN (versión papel): 2605-1648.
  88. Adriana Sánchez-Danés, Jean-Christophe Larsimont, Mélanie Liagre, Eva Muñoz-Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, Véronique del Marmol, Josep Tabernero & Cédric Blanpain A slow cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 562, 434-438 (2018). ISSN: 1476-4687. DOI: 10.1038/s41586-018-0603-3
  89. J. Ros, E. Muñoz-Couselo. DRESS syndrome due to Vemurafenib treatment: switching BRAF inhibitor to solve a big problem. BMJ Case Rep 2018 Sep 30;2018: bcr2018224379. doi: 10.1136/bcr-2018-224379.
  90. Mar Riveiro-Barciela, Eva Muñoz-Couselo; Jesús Fernandez-Sojo; Nelly Diaz-Mejia; Rafael Parra-López; María Buti. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol. 2019 Mar;70(3):564-566. doi: 10.1016/j.jhep.2018.10.020.
  91. Eva Muñoz- Couselo, Enrique Espinosa. Carcinoma de células de Merkel: estadiaje y radioterapia. Revista cáncer de piel. Volumen 2 Num extraordinario 1, páginas 14-18, 2019
  92. Joaquín Gavilá; Juan De La Haba; Begoña Bermejo; Álvaro Rodríguez-Lescure; Antonio Antón; Eva Ciruelos; Joan Brunet; Eva Muñoz-Couselo; Marta Santisteban; César Augusto Rodríguez Sánchez; Ana Santaballa; Pedro Sánchez Rovira; José Ángel García-Sáenz; Manuel Ruiz Borrego; Ángel Guerrero-Zotano; Marisol Huerta; Almudena Cotes-Sanchís; Juan Lao Romera; Elena Aguirre; Javier Cortés; Antonio Llombart-Cussac. «A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: The Trastyvere study’. Clinical and Translational Oncology 2019. https://doi.org/10.1007/s12094-019-02145-4
  93. Omid Hamid, Luciana Molinero, Christopher Bolen, Jeffrey A. Sosman, Donald P. Lawrence, Eva Muñoz-Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fasso, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from Phase I trial of Atezolizumab. Clinical Cancer Research. July 29, 2019 doi: 10.1158/1078-0432.CCR-18-3488
  94. Ros-Montañá, Javier; Saoudi-Gonzalez, Nadia; Ortiz-Velez, Carolina; Muñoz-Couselo, Eva. The role of ipilimumab after anti-PD-1 treatment two case reports and a literature review. Melanoma Research: 2020 Apr;30(2):209-212. doi: 10.1097/CMR.0000000000000632.
  95. Dirk Schadendorf, MD; Paolo A Ascierto; John Haanen; Enrique Espinosa; Lev Demidov; Claus Garbe; Michele Guida; Paul Lorigan; Vanna Chiarion-Sileni; Helen Gogas; Michele Maio; Maria Teresa Fierro; Christoph Hoeller; Patrick Terheyden; Ralf Gutzmer; Tormod K Guren; Dimitrios Bafaloukos; Piotr Rutkowski; Ruth Plummer; Ashita Waterston; Martin Kaatz; Mario Mandala; Ivan Marquez-Rodas; Eva Muñoz-Couselo; Reinhard Dummer; Elena Grigoryeva; Tina C Young; Paul Nathan. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). European Journal of Cancer 121 (2019) 144e153
  96. P. Nathan, P.A. Ascierto, J. Haanen, E. Espinosa, L. Demidov, C. Garbe, M. Guida, P. Lorigan, V. Chiarion-Sileni, H. Gogas, M. Maio, M.T. Fierro, C. Hoeller, P. Terheyden, R. Gutzmer, T. Guren, D. Bafaloukos, P. Rutkowski, R. Plummer, A. Waterston, M. Kaatz, M. Mandala, I. Marquez-Rodas, E. Muñoz-Couselo, R. Dummer, E. Grigoryeva, T. Young, D. Schadendorf. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase 2 study (CheckMate 172). Eur J Cancer 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21.
  97. Peter Mohr, Felix Kiecker, Virtudes Soriano Teruel, Olivier Dereure, Karmele Mujika, Philippe Saiag, Jochen Utikal, Rama Koneru, Caroline Robert, James Larkin, Florencia Cuadros, Matias, Rodrigo Villaroel, Yana Najjar, Lisa Kottschade, Eva Muñoz Couselo, Jonathan Zager. Adjuvant Therapy versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multi-Country Retrospective Chart Review. Melanoma Management 2019. doi:10.2217/mmt-2019-0015
  98. Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa del Olza, Cristina Viaplana, Analia Azaro, Maria Vieito, Irene Braña, Gemma Mur, Javier Ros, Jose Mateos, Mafalda Oliveira, Maria Alsina1, Elena Elez, Ana Oaknin1, Eva Muñoz-Couselo, Joan Carles, Enriqueta Felip Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Raquel Perez-Lopez and Elena Garralda. Capturing Hyperprogression disease with immune checkpoint inhibitors using RECIST 1.1 criteria. Clinical Cancer Research 2019 Nov 22. pii: clincanres.2226.2019. doi: 10.1158/1078-0432.CCR-19-2226
  99. María Julia Lostes Bardaji MD, Carolina Ortiz MD, Analía Azaro MD, Eva Muñoz-Couselo MD PhD. Opciones emergentes en terapias de combinación para el melanoma avanzado (MM): Un nuevo desafío. Cáncer de piel 2019. IS-SN papel 2605-1648, electrónica IS-SN 2605-1669.
  100. Margarita Majem, M.D.; Elena García-Martínez; María Martínez García; Eva Muñoz-Couselo; Delvys Rodríguez Abreu; Ruth Álvarez Cabello; Ana Arance; Alfonso Berrocal; Luis de la Cruz-Merino; Jose A. López-Martin. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clinical and translational oncology 2020.
  101. Peter Schmid, Robeto Salgado, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Joohyuk Sohn, Seock-Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kuemme, Rebecca Dent, Lina Yin, Anran Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés Sherene Lo.i Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-label, Multicohort KEYNOTE-173 Study. Annals of oncology 2020.
  102. Mónica Bolufer, Clara Garcia Carro, Roxana Bury, Eva Muñoz, Enriqueta Felip, Alejandra Gabaldon, Maria Jose Carreras, Daniel Seron Micas, María José Soler. Clinical characteristics and independent predictors of check point inhibitors-associated aki: what do we know? Nephrology Dialysis Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa141.TO017,https://doi.org/10.1093/ndt/gfaa141.TO017.
  103. Mar Riveiro-Barciela1, Judit Vidal-González, Ana Barreira-Díaz, Eva Muñoz-Couselo, Lluís Viladomiu, Beatriz Mínguez, Carolina Ortiz Velez, Fernando Martínez-Valle, Lluís Castells, Rafael Esteban, María Buti. Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors. Liver international August 2020, Pages 1906-1916.
  104. Maria Gonzalez-Cao,MD; Mónica Antoñanzas Basa, MD; Teresa Puertolas, MD; Eva Muñoz-Couselo, MD; José Luis Manzano, MD; Cristina Carrera, MD; Ivan Marquez, MD; Pilar Lopez Criado, MD; Juan Francisco Rodriguez Moreno, MD; Almudena García Castaño, MD; Juan Martín Liberal, MD; Pedro Rodríguez-Jiménez, MD; Susana Puig, MD; Pablo Cerezuela, MD; Marta Feito Rodríguez, MD; Belén Rubio Viqueira, MD; Guillermo Crespo, MD; Pablo Luna Fra, MD; Cristina Aguayo Zamora, MD; Pablo Ayala de Miguel, MD; Rosa Feltes Ochoa, MD; Lara Valles, MD; Ana Drozdowskyj, PhD; Alfonso Berrocal, MD, for the Spanish Melanoma Group (GEM). Anti cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients. May, 2020 https://doi.org/10.1101/2020.05.19.20106971
  105. Diana Oleas, Mónica Bolufer1, Irene Agraz1, Enriqueta Felip, Eva Muñoz, Alejandra Gabaldón, Roxana Bury, Eugenia Espinel, Daniel Serón, Clara García-Carro, María José Soler. Acute interstitial nephritis associated with immune checkpoint inhibitors: A 12-month single center experience. Clinical Kidney Journal, 10 February 2020. doi: 10.1093/ckj/sfaa008
  106. Mar Riveiro-Barciela, Ernesto Trallero-Araguás, María Roca-Herrera4, Ester Zamora, Ana Barreira-Díaz, Eva Muñoz-Couselo, Fernando Martínez-Valle. Toxicities from immunotherapy: from clinical trials to the real-world clinical practice. Medicina clínica 2020
  107. Ana Amor Lopez, Marina S. Mazariegos, Marta Hergueta-Redondo, Alessandra Capuano, Pilar Ximénez-Embún, Osvaldo Graña-Castro, Javier Muñoz, Juan Ángel Recio, Eva Muñoz, Diego Megías, Roberto Doliana, Paola Spessotto and Héctor Peinado. Emilin1 degradation and secretion in exosomes inactivate its tumor- and metastasis-suppressive role in melanoma mouse models. Nature communications, Communications Biology 2020; Int J Mol Sci. 2021 Jul; 22(14): 7406, doi: 10.3390/ijms22147406
  108. A. Hernando-Calvo, A. Garcia-Alvarez, G. Villacampa, C. Ortiz, D. Bodet, V. Garcia-Patos, J.A Recio, R. Dienstmann, E. Muñoz-Couselo. Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients. Clinical and Translational Oncology Clin Transl Oncol 2021 Feb;23(2):311-317. doi: 10.1007/s12094-020-02420-9. Epub 2020 Jun 19.
  109. Paula Granado-Martinez, Elena González-Sánchez, Sara García Ortega, Kimberley McGrail, Rafael Selgas, Judit Grueso, Rosa Gil, Javier Hernandez-Losa, Berta Ferrer, Josep Villanueva, Olga Méndez, Sergio Espinosa-Gil, José M. Lizcano, Eva Muñoz-Couselo, Vicenç GarcíaPatos and Juan A. Recio. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Nature cancer/ Communications Biology 3, Article number: 366 (2020); DOI: 10.1038/s42003-020-1092-0
  110. Maria Gonzalez-Cao, MD; Teresa Puertolas, MD; Mar Riveiro-Barciela, MD; Eva Muñoz-Couselo, MD; Carolina Ortiz6; Roger Paredes-8, MD; Daniel Podzamczer, MD; José Luis Manzano, MD; Jose Molto, MD; Boris Revollo, MD; Cristina Carrera, MD; Lourdes Mateu, MD; Sara Fancelli, MD; Enrique Espinosa, MD; Bonaventura Clotet, MD; Javier Martinez-Picado , PhD; Mario Mandala, MD; Alfonso Berrocal, MD, for the Spanish Melanoma Group (GEM). Cancer Immunotherapy in Special Challenging Populations: Recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). MedRxiv 2020. 05.19.20106971; doi :https: 10.1101/2020.05.19.20106971
  111. Maria Gonzalez-Cao, MD; Teresa Puertolas, MD; Mar Riveiro-Barciela, MD; Eva Muñoz-Couselo, MD; Carolina Ortiz6; Roger Paredes-8, MD; Daniel Podzamczer, MD; José Luis Manzano, MD; Jose Molto, MD; Boris Revollo, MD; Cristina Carrera, MD; Lourdes Mateu, MD; Sara Fancelli, MD; Enrique Espinosa, MD; Bonaventura Clotet, MD; Javier Martinez-Picado, PhD; Mario Mandala, MD; Alfonso Berrocal, MD, for the Spanish Melanoma Group (GEM). Cancer Immunotherapy in Special Challenging Populations: Recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). Journal for ImmunoTherapy of Cancer 2021.
  112. Eva Muñoz- Couselo. Cáncer cutáneo de células escamosas: Inmunoterapia: inhibidores de checkpoints. Rev Cáncer de Piel 20213 (extra.1): 33-36. ISN papel 2605-1648, ISN electrónico 2605-1699.
  113. Maria González Cao, Cristina Carrera, Juan Rodriguez-Moreno, Pedro Rodriguez-Jimenez, Monica Antoñanzas Basa, Rosa Feltes Ochoa, Teresa Puertolas, Eva Muñoz Couselo, Jose Luis Manzano, Ivan Marquez-Rodas, Juan Martin-Liberal, Ainara Soria, Pilar Lopez Criado, Almudena Garcia-Castaño, Aram Boada, Pablo Ayala de Miguel, Susana Puig, Guillermo Crespó, Pablo Luna, Cristina Aguayo, Marta Feito, Lara Valles, Ana Drozdowskyj, Cayetana Maldonado Seral, Jesus Gardeazabal, Laura Villalobos, Rafael Rosell, Luis Antonio Luis Antonio Fernandez-Morales, Alberto Rodrigo, Santiago Viteri, Mariano Provencio, and Alfonso Berrocal. COVID-19 in Melanoma Patients: Results of the Spanish Melanoma Group Registry, GRAVID study. Journal of the American Academy of Dermatology 2021. https://doi.org/10.1016/j.jaad.2021.02.013
  114. Clara García-Carro, MD, PhD; Mónica Bolufer, MD; Roxana Bury, MD; Zaira Catañeda, MD; Eva Muñoz-Couselo, MD, PhD; Enriqueta Felip, MD, PhD; David Lorente, MD, PhD; María Josep Carreras, MD, PhD; Alejandra Gabaldon, MD, Irene Agraz, MD, PhD; Daniel Serón, MD, PhD; María José Soler, MD, PhD. Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors. Nephrology Dialysis Transplantation 2021. PMID: 33547795; DOI:10.1093/ndt/gfab034
  115. Carlos González-Cruz, Domingo Bodet, Eva Muñoz-Couselo, Vicente García-Patos. Mediastinal FDG-positive lymph nodes simulating melanoma progression: drug-induced sarcoidosis like/lymphadenopathy related to ipilimumab. BMJ Case Reports, January 28, 2021. http://dx.doi.org/10.1136/bcr-2020-237310
  116. Eric P. Winer, MD, Oleg Lipatov, MD, Seock-Ah Im, MD, Anthony Goncalves, MD, Eva Muñoz-Couselo, MD5, Keun Seok Lee, MD, Zbigniew Nowecki, MD, Peter Schmid, MD, Kenji Tamura, MD, Laura Testa, MD1 Isabell Witzel, MPH, Shoichiro Ohtani, MD, Nicholas Turner, MD, Stefania Zambelli, MD, Nadia Harbeck, MD, Fabrice Andre, MD, Rebecca Dent, MD, Xuan Zhou, PhD, Vassiliki Karantza, MD, Jaime Mejia, MD Javier Cortes, MD. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncology 2021. https://doi.org/10.1016/ S1470-2045(20)30754-3
  117. Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, Curigliano G, Muñoz-Couselo E, Perez-García J, Marti M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Eur J Cancer. 2021 May; 148:134-145. doi: 10.1016/j.ejca.2021.01.037. Epub 2021 Mar 17. PMID: 33743482.
  118. Eva Muñoz-Couselo MD PhD. Cáncer cutáneo de células escamosas: Inmunoterapia: inhibidores de checkpoints. Cáncer de piel, volumen 4 número extraordinario 2021 (1). IS-SN papel 2605-1648, electrónica IS-SN 2605-1669.
  119. Noelia Nebot, Christina S. Won2, Victor Moreno, Eva Muñoz-Couselo, Dung-Yang Lee, Eduard Gasal, and Emmanuel Bouillaud. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate). Clinical Pharmacology in Drug Development 2021. doi: 10.1002/cpdd.937
  120. Ignacio Matos, Guillermo Villacampa, Cinta Hierro, Juan Martin-Liberal, Roger Berché, Anna Pedrola, Irene Braña, Analia Azaro, Maria Vieito, Omar Saavedra, Itziar Gardeazabal, Alberto Hernando1, Guzmán Alonso, Vladimir Galvao, Javier Ros, Cristina Viaplana, Eva Muñoz-Couselo, Elena Elez, Jordi Rodon, Cristina Saura, Teresa Macarulla, Ana Oaknin, Joan Carles, Enriqueta Felip, Josep Tabernero, Rodrigo Dienstmann and Elena Garralda. Phase I prognostic online (PIPO) tool: a new aid to improve patient selection for early phase clinical trials. European Journal Cancer 2021
  121. Alejandro Garcia-Alavarez, Carolina Ortiz, Eva Muñoz-Couselo. Current Perspectives and Novel Strategies of NRAS-mutant melanoma. OncoTargets and Therapy 2021:14 3709–3719
  122. B. G. M. Hughes, E. Munoz-Couselo, L. Mortier, Å. Bratland4, R. Gutzmer, O. Roshdy, R. González Mendoza, J. Schachter, A. Arance, F. Grange N. Meyer, A. Joshi, S. Billan, P. Zhang, B. Gumuscu, R. F. Swaby, J-J Grob. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial. Ann Oncol. 2021 Jul 19: S0923-7534(21)02186-4. doi: 10.1016/j.annonc.2021.07.008. Online ahead of print. PMID: 34293460
  123. Ana Amor Lopez, Marina Mazariegos, Marta Hergueta-Redondo, Alessandra Capuano, Pilar Ximénez-Embún, Héctor Tejero, Javier Muñoz, Juan Recio, Eva Muñoz-Couselo, Roberto Doliana, Roberto Doliana, Paola Spessotto, and Hector Peinado. Inactivation of EMILIN-1 by proteolysis and secretion in extracellular vesicles favours melanoma progression and metástasis. Int. J. Mol. Sci. 2021, 22, 7406. https://doi.org/10.3390/ ijms22147406
  124. Mar Riveiro-Barciela,  Didac González-Sans, David Marmolejo,  Maria-Teresa Salcedo, Eva Muñoz-Couselo. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors.  Gastrointestin Liver Dis. 2021 Mar 13;30(1):171-172. doi: 10.15403/jgld-3207.
  125. Maria Gonzalez-Cao1; Clara Mayo de las Casas1; Juana Oramas2; Miguel A Berciano3; Luis de la Cruz4; Pablo Cerezuela5; Ana Arance6; Eva Muñoz7; Enrique Espinosa8; Teresa Puertolas9; Roberto Diez10; Sebastian Ochendustko11; Maria Jose Villanueva12; Laura Basterretxea13; Lorena Bellido14; Delvys Rodriguez15; Begoña Campos16; Clara Montagut17; Ana Drozdowskyj1; Miguel A Molina1; Jose Antonio Lopez-Martin18; Alfonso Berrocal19 for the Spanish Melanoma Group (GEM). Intermittent BRAF inhibition in advanced BRAF mutated melanoma:  results of a phase II randomized trial. Nature communications 2021 2:7008 | https://doi.org/10.1038/s41467-021-26572-6
  126. Álamo MC, Ochenduszko S, Crespo G, Corral M, Oramas J, Sancho P, Medina J, Garicano F, LópezP, Campos Balea B, Rodríguez Garzotto A, Muñoz-Couselo E. Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. OncoTargets and Therapy, November 2021 Volume 2021:14, Pages 5345—5352. DOI https://doi.org/10.2147/OTT.S325208
  127. Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119. doi: 10.1148/radiol.2021200928. Epub 2021 Jan 26. PMID: 33497314.
  128. Clara García-Carro 1, Mónica Bolufer 1, Roxana Bury 1, Zaira Castañeda 1, Eva Muñoz 2, Enriqueta Felip 2, David Lorente 3, María Josep Carreras 4, Alejandra Gabaldon 5, Irene Agraz 1, Daniel Serón 1, María José Soler . Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant 2022 Apr 25;37(5):887-894. doi: 10.1093/ndt/gfab034.
  129. Riveiro-Barciela M, Barreira-Díaz A, Callejo-Pérez A, Muñoz-Couselo E, Díaz-Mejía N, Díaz-González Á, Londoño MC, Salcedo MT, Buti M. Retreatment with Checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study. Clin Gastroenterol Hepatol. 2022 Apr 26: S1542-3565(22)00403-7. doi: 10.1016/j.cgh.2022.03.050.
  130. Laia Aceituno, Juan Bañares, Lourdes Ruiz, Ana Callejo-Pérez, Eva Muñoz-Couselo, Carolina Ortiz-Velez, Nely Díaz-Mejía, Ana Barreira-Díaz, María José Carreras, Anna Farriols, María Buti, Mar Riveiro-Barciela. The low incidence of HBV reactivation among positive anti-HBc subjects on immunotherapy reduces the impact of suboptimal screening rate. Front. Med. Sec. Translational Medicine, doi: 10.3389/fmed.2022.916213
  131. Mònica Sabaté Gallego1,2, Eulàlia Pérez Esquirol1, Núria Garcia Doladé3, Xavier Vidal Guitart1,2, Maria-Josep Carreras Soler4, Anna Farriols Danés4, Enriqueta Felip5,6, Irene Braña5,6, Joan Carles Galceran5,6, Rafael Morales Barrera5,6, Eva Muñoz- Couselo5,6, Antonieta Agustí Escasany1, Incidence and characteristics of adverse drug reactions in a cohort of patients treated with immunotherapy in real-world practice. Front. Med., 22 August 2022. Sec. Translational Medicine: https://doi.org/10.3389/fmed.2022.891179
  132. Jeffrey Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolas Meyer, PaoloA. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel Tenney, Hao Tang, Georgina V. Long. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Stage IIIB–D or Stage IV Melanoma (CheckMate 915). J Clin Oncol. 2022; doi:10.1200/JCO.22.01770
  133. Guillermo Villacampa1,2,3, Alberto Hernando1,4, Roger Berché1, Omar Saavedra1,4, David Marmolejo1,4, Oriol Mirallas4, Irene Braña1,4, Eva Muñoz-Couselo1,4, Elena Garralda1,4, Rodrigo Dienstmann1#. Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias”. Cancer Treatment Reviews Cancer Treatment Reviews, September 23, 2022; DOI: https://doi.org/10.1016/j.ctrv.2022.102465
  134. Ester Bonfill-Teixidor, Raffaella Iurlaro, Cornelia Handl, Jürgen Wichmann, Alexandra Arias, Isabel Cuartas, Jasmin Emmenegger, Luca Mangano, Thomas Lorber, Marco Berrera, Christina Godfried Sie, Köchl Fabian, Jan Eckmann, Romi Feddersen, Martin Kornacker, Gabriel Schnetzler, Thomaz Topczewski, Abel Ferres-Pijoan, Josep Gonzalez, Francisco Martínez-Ricarte, Eva Muñoz-Couselo, Josep Tabernero, James Bischoff, Piergiorgio Pettazzoni, and Joan Seoane. Activity and resistance of a brain permeable paradox breaker BRAF inhibitor in melanoma brain metastasis. Cancer Res 2022 Jul 18;82(14):2552-2564.  doi: 10.1158/0008-5472.CAN-21-4152.
  135. Kimberley McGrail, Ms Sara García-Ortega, Paula Granado-Martinez, Dr Rosaura Estéve-Puig, Ms Sara Sanchez-Redondo, Dr Berta Ferrer, Dr Javier Hernandez-Losa, Dr Francesc Canals, Dr Anna Manzano, Aurea Navarro-Sabaté , Ramon Bartrons , Dr Mileidys Pérez-Alea , Eva Muñoz Couselo , Vicenç Garcia-Patos. BRAF activation by metabolic stress promotes glycolysis and survival, sensitizing NRASQ61 mutated melanomas to targeted therapy. Nature Communications | (2022) 13:7113; https://doi.org/10.1038/s41467-022-34907-0
  136. Maria Lozano-Rabella1, Andrea Garcia-Garijo1, Jara Palomero1, Anna Yuste-Estebanez1, Florian Erhard2, Juan Martín-Liberal3, Ignacio Matos3, Jared J. Gartner4, Steven A. Rosenberg4, Michael Ghosh5, Francesc Canals6, August Vidal7, Josep Maria Piulats8, Xavier Matias-Guiu8, Irene Braña3, Eva Muñoz- Couselo9, Elena Garralda3, Andreas Schlosser2, Alena Gros1. Immunogenicity of non-canonical HLA-I tumor ligands identified through proteogenomics. bioRxiv 2022.11.07.514886 11/2022; doi:ps://doi.org/10.1101/2022.11.07.514886
  137. Selina K. Wong1, Steven M. Blum2,3, Xiaopeng Sun1, Inês Pires Da Silva4, Leyre Zubiri2, Fei Ye5, Kun Bai5, Kevin Zhang5, Selma Ugurel6, Lisa Zimmer6, Elisabeth Livingstone6, Dirk Schadendorf6, Patricio Serra-Bellver7, Eva Muñoz-Couselo8, Carolina Ortiz8, Julia Lostes8, Roberto Martín Huertas9, Ana Arance9, Lisa Pickering10, Georgina V. Long4,11,12, Matteo S. Carlino13, Elizabeth I. Buchbinder3, Leticia Vázquez-Cortés14, Diego Jara-Casas15, Iván Márquez-Rodas16, Iván R. González-Espinoza17, Justin M. Balko1, Alexander M. Menzies4,11,12, Ryan J. Sullivan2, and Douglas B. Johnson1. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. European Journal of Cancer 2022, https://doi.org/10.1016/j.ejca.2022.12.013

Projectes

Public and Competitive Funding:

  1. TANGERINE Project Project title: Artificial intelligence for the prediction of response to cancer immunotherapy.Funding body: Instituto de Salud Carlos III (ISCIII) Duration: 01/01/2023 – 01/01/2025 Role: Principal Investigator This project focuses on the application of artificial intelligence tools to improve prediction of response to immunotherapy, contributing to precision oncology strategies.
  2. SEOM Translational Research Grant 2024 (Immuno-Oncology) Project title: Ultrasensitive liquid biopsy as a biomarker of minimal residual disease and risk of recurrence in patients with operable melanoma.Funding body: Sociedad Española de Oncología Médica (SEOM) Award date: October 17, 2024 (Madrid) Role: Principal Investigator This translational project aims to validate high-sensitivity ctDNA approaches for minimal residual disease detection and relapse risk stratification in resectable melanoma.

Industry-Sponsored Competitive Research Projects:

  1. Grantor: Roche Farma S.A. Project title: Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation who achieve response (CR/PR) after at least one year of treatment with cobimetinib plus vemurafenib in routine clinical practice. Duration: 28/04/2017 – 31/12/2025 Principal Investigator: Eva Muñoz
  2. Grantor: Merck Sharp & Dohme de España, S.A. Project title: Support for research projects in the field of melanoma and cutaneous tumors. Duration: 21/11/2019 – 31/12/2025 Principal Investigator: Eva Muñoz
  3. Grantor: Bristol-Myers Squibb International Corporation (BMSIC) Project title: Phase II study comparing early detection of asymptomatic brain metastases versus standard follow-up on overall survival and symptomatic brain metastasis–free survival in patients with previously untreated unresectable or metastatic melanoma. Duration: 10/12/2019 – 31/12/2025 Principal Investigator: Eva Muñoz

1. Genetic profile of benign dermal lesions.
2. The emergence of a Ferroptosis-inhibiting mutation was the caused to the acquired resistance to IO in p136 patient.
3. Genetic profiling of squamous cell carcinomas.
4. Stage IIIA melanoma outcomes.
5. Role of LIF regulating Immunoresponse in melanoma.
6. Seguridad del retratamiento con inhibidores de checkpoint en pacientes oncológicos con antecedente de hepatitis inmunomediada grave (estudio RECIPHI).
7. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
8. Improving melanoma targeted and Immunothereapies using nanotecnology.
9. Role of p38α in antitumoral immune response and immunotherapy resistance.
10. Predicción de la respuesta a fármacos inhibidores de BRAF en pacientes de melanoma.
11. Biopsia líquida para detección nanoplasmónica de exosomas: prediciendo respuesta a la inmunoterapia.
12. 360º RESISTANCE: Aplicación de un modelo de investigación traslacional para estudiar predictores de respuesta/toxicidad, y mecanismos de resistencia en pacientes tratados con inmunoterapia.
13. Estrategias específicas para el cerebro para mejorar la respuesta a inmunoterapia.
14. Estudio de mecanismos de resistencia primaria y adquirida a inhibidores de immune checkpoints.
15. Estudio observacional descriptivo sobre las características y evolución del melanoma avanzado y metastásico en España GEM 1801.
16. Búsqueda de marcadores predictores de corticoterapia en hepatitis inmunomediadas (Estudio HEPiraes).
17. Genetic profiling of squamous cell carcinomas
18. Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immunetherapies
19. Identification y characterization of slow cyclin cells in vivo using melanoma PDX.
20. Study of the cooperation of the stress pathway (MAPK14) in melanoma development, progression and intra-tumoral immune response for therapeutic purposes.
21. Aldehyde oxydation metabolism in melanoma
22. Melanoma Biobank.

Notícies Relacionades

Mafalda Oliveira exterior con bata VHIO
Un nou fàrmac oral aprovat per l’EMA per a càncer de mama RH+/HER2- presenta beneficis clínics i preserva la qualitat de vida de les pacients durant més temps

Avui es publiquen a la revista The Lancet Oncology els resultats reportats per les pacients respecte a la qualitat de…

28 ag. 2024
Pañuelo solidario
La 5a edició del “Mocador Solidari” impulsa la recerca contra el càncer de la dona i ofereix recursos per acompanyar emocionalment les pacients amb càncer de mama

Els beneficis es destinen als projectes de dues joves investigadores del Vall d’Hebron Institut de Recerca (VHIR) i el Vall…

18 oct. 2022
Debat CaixaResearch sobre els avenços en la detecció precoç del càncer mitjançant biòpsia líquida

Les investigadores Olga Vera (Instituto de Investigación Sanitaria del Hospital Universitario de La Paz, IdiPaz), Lorena Diéguez (Laboratorio Ibérico Internacional…

22 febr. 2024
Practica clinica
SEOM fa un nou lliurament de les seves beques per a Oncologia Mèdica amb un paper destacat de VHIO

Fins a sis professionals del Vall d’Hebron Institut d’Oncologia (VHIO), que forma part del Campus Vall d’Hebron, es podran beneficiar…

20 oct. 2022
El Paseíco de la Mama finança una investigació sobre la resposta a tractament en pacients de càncer de mama metastàtic segons el seu estatus genètic

Després de dues edicions marcades per la pandèmia, el Paseíco de la Mama va tornar a celebrar-se amb normalitat el…

27 gen. 2023
Cristina Saura
Afegir un nou fàrmac a la combinació estàndard millora la supervivència en pacients amb càncer de mama metastàtic amb mutacions en el gen PIK3CA

L’assaig clínic fase 3 INAVO120 demostra l’eficàcia d’afegir el fàrmac inavolisib al tractament estàndard amb palbociclib-fulvestrant en pacients amb càncer…

31 maig 2025
Nova edició de la Pink Run Mir, una cursa a favor de la investigació del càncer de mama lobulillar

El proper 16 d’octubre tindrà lloc la 5a edició de la Pink Run Mir, una cursa solidària que cerca reunir…

07 oct. 2022
Afegir un nou fàrmac oral al tractament estàndard millora els resultats clínics en pacients amb càncer de mama metastàtic HR+ HER2- prèviament tractades

En tumors HR+ HER2- metastàtics, la primera línia de tractament estàndard són els inhibidors de CDK4/6 en combinació amb teràpia…

19 juny 2023
Mafalda Oliveira exterior con bata VHIO
Patritumab deruxtecan redueix efectes secundaris greus en pacients amb càncer de mama comparat amb la quimioteràpia convencional mantenint l’eficàcia del tractament

Els resultats de l’estudi SOLTI-2103 VALENTINE demostren que el conjugat fàrmac-anticòs patritumab deruxtecan -en la dosi i l’esquema de tractament…

11 des. 2024
Mafalda Oliveira exterior con bata VHIO
SOLTI llança el nou estudi HOPE-Focus per a pacients amb càncer de mama metastàtic i consolida el programa HOPE com a pioner en oncologia de precisió

Els resultats del primer estudi HOPE, presentats a finals de 2023, han impulsat un nou estudi dins del mateix programa,…

21 maig 2025
La caminada El Paseíco de la mama donarà suport a una investigació sobre la resposta al tractament amb inhibidors de ciclines CDK4/6 en funció de l’estatus genètic en pacients amb càncer de mama metastàtic

El Paseíco de la Mama és una tradicional caminada de 7,5 quilòmetres al llarg del canal de Saragossa amb familiars,…

07 oct. 2022
Josep Tabernero 2025
Un innovador anticòs biespecífic millora els resultats clínics de pacients amb càncer gàstric HER2+ avançat en primera línia

L’assaig clínic de fase 3 HERIZON-GEA-01 compara l’eficàcia de l’anticòs biespecífic zanidatamab més quimioteràpia amb o sense tislelizumab en front…

28 maig 2026
Santiago Escrivà VHIO
L’addició de palbociclib al tractament incrementa 15 mesos la supervivència sense avenç de la malaltia a les pacients amb càncer de mama metastàtic RH+/HER2+

Els resultats de l’estudi de fase III PATINA, coordinat per SOLTI a Espanya i Portugal, demostren que afegir palbociclib com…

19 des. 2024
Dra. Eva Muñoz-Couselo
VHIO participa en un estudi que confirma la immunoteràpia amb anti-PD1 en monoteràpia com la millor opció per als pacients afectats de melanoma d’alt risc

Així es desprèn dels resultats de l’estudi CheckMate 915, en què ha participat la Dra. Eva Muñoz-Couselo, investigadora del Grup…

13 oct. 2022
Dos projectes de VHIO guardonats al V Premi M. M. Chiara Giorgetti a la investigació en càncer de mama metastàtic de l’Associació Espanyola Càncer de Mama Metastàtic

El Premi M. Chiara Giorgetti és organitzat anualment per l’AECMM per promoure la investigació específica en càncer de mama metastàtic…

15 des. 2023
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required